Last reviewed · How we verify

Open Label Treatment Access: Maraviroc

ViiV Healthcare · Phase 2 active Small molecule

Open Label Treatment Access: Maraviroc is a Small molecule drug developed by ViiV Healthcare. It is currently in Phase 2 development. Also known as: Maraviroc, Celsentri, Selzentry.

At a glance

Generic nameOpen Label Treatment Access: Maraviroc
Also known asMaraviroc, Celsentri, Selzentry
SponsorViiV Healthcare
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Open Label Treatment Access: Maraviroc

What is Open Label Treatment Access: Maraviroc?

Open Label Treatment Access: Maraviroc is a Small molecule drug developed by ViiV Healthcare.

Who makes Open Label Treatment Access: Maraviroc?

Open Label Treatment Access: Maraviroc is developed by ViiV Healthcare (see full ViiV Healthcare pipeline at /company/viiv-healthcare).

Is Open Label Treatment Access: Maraviroc also known as anything else?

Open Label Treatment Access: Maraviroc is also known as Maraviroc, Celsentri, Selzentry.

What development phase is Open Label Treatment Access: Maraviroc in?

Open Label Treatment Access: Maraviroc is in Phase 2.

Related